Lipum publishes positive phase I results for SOL-116
The results were published in RMD Open and show good safety, dose proportionality, and target binding.
See the latest news and media coverage for Lipum. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biopharmaceutical company focused on chronic inflammatory diseases
lipum.seLast updated
In short: Lipum completed a merger with Flerie AB and secured an €8 million Horizon Europe grant to advance SOL-116 into Phase IIa clinical trials.
The results were published in RMD Open and show good safety, dose proportionality, and target binding.
The BEYOND project will advance the company's research and development of new therapies.
The grant from Horizon Europe funds the SOL-116 phase IIa study on rheumatoid arthritis in collaboration with partners.
The Companies Registration Office has registered the merger. Lipum's assets are transferred to Flerie, which retains the name and seat in Stockholm.
The merger between investment firm Flerie and pharmaceutical company Lipum has now been finalized, according to a press release.Under the terms of the transaction, Lipum...
Redeye ceases its coverage of Lipum and will not provide research on the company following the completion of the merger between Flerie and Lipum and...
The Swedish Companies Registration Office (Sw. Bolagsverket) has granted permission to Flerie AB (publ) (“Flerie”) to carry out the merger plan concerning the merger between...
A signed agreement with the European Commission would mean a significant capital injection without any dilution of ownership. Lipum leads a European consortium consisting of...
Track Lipum and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Lipum and other trending companies.